Meg Lindsay

Meg Lindsay, R.N. is an experienced healthcare professional with a robust background in clinical operations and project management. Currently serving as Executive Director at Daiichi Sankyo, Inc. since September 2022, Meg previously held various leadership roles at GSK, including US Head of Clinical Operations INTERIM and Director of Clinical Development in Cell and Gene Therapy from April 2019 to September 2022. Prior to GSK, Meg was a Senior Project Director at Precision Oncology from September 2014 to 2019 and spent over a decade at AstraZeneca in multiple roles, including Director of Global Medicine Development Operations. Meg holds a Bachelor of Science in Nursing from Jefferson Health and a Project Management Certificate from Villanova University, obtained in 2011.